The main component in Diflucan - Fluconazole selectively works for fungal cytochrome P450 dependent enzyme lanosterol 14-α-demethylase. The medicine stops the transformation of lanosterol to ergosterol induced by fungal cytochrome enzyme.
Diflucan has demonstrated high activity against the following fungi:
Fluconazole may also be used as a therapy for the following microorganisms though its efficacy has not been proven by the clinical experience:
Other types of Candida (especially superinfections) are considered to be resistant to the action of fluconazole. However in some cases this medicine may be observed as an adjunct or alternative therapy for certain conditions (superinfections) caused by Candida.
Diflucan for oral use has shown max plasma concentrations within 1-2 hours post oral administration. Plasma concentrations of the drug are dose-propotional. The half-life of the medicine ranges from 20 up to 50 hours.
The food does not affect the rate of absorption of the drug. The medicine can be used with or without food.
The persistent concentrations of the medicine are obtained within 5–10 days using the single oral doses of 50–400 mg.
Diflucan plasma protein binding is about 11–12%. The medicine easily penetrates into skin, saliva, cerebrospinal fluid, sputum, urine, vaginal tissue and in vaginal fluid.
The medicine is cleared by kidneys. The elimination of 80% of the drug is in the urine. Patients with kidney disorders may have reduced rate of clearance of the medicine. They should receive only half of the normal dose of the medicine.